Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pilot study to evaluate of the impact on bone density during treatment with mycophenolate mofetil, daclizumab in combination with ciclosporin converted to sirolimus with steroid as mainstay immunosuppression, in comparison to current standard immunosuppression (daclizumab, mycophenolate, ciclosporin and corticosteroids) in renal transplantation

Next Previous
Trial Profile

A pilot study to evaluate of the impact on bone density during treatment with mycophenolate mofetil, daclizumab in combination with ciclosporin converted to sirolimus with steroid as mainstay immunosuppression, in comparison to current standard immunosuppression (daclizumab, mycophenolate, ciclosporin and corticosteroids) in renal transplantation

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sirolimus (Primary) ; Ciclosporin; Corticosteroids; Daclizumab; Mycophenolate mofetil
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Acronyms Bone Protection study

    • Most Recent Events

    • 28 Feb 2019 Status changed from recruiting to discontinued.
    • 12 Aug 2011 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top